Dr. Wesolowski is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
460 W 10th Ave
Columbus, OH 43210Phone+1 614-293-6529Fax+1 614-293-9429
Education & Training
- Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2007 - 2010
- Cleveland Clinic FoundationResidency, Internal Medicine, 2004 - 2007
- State University of New York Downstate Medical Center College of MedicineClass of 2004
Certifications & Licensure
- OH State Medical License 2004 - 2025
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I Start of enrollment: 2011 Oct 01
- Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors Start of enrollment: 2012 May 01
- AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Subjects With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy Start of enrollment: 2016 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 57 citationsPhase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.Aditya Bardia, Virginia G. Kaklamani, Sharon Wilks, Amy Weise, Donald A. Richards
Journal of Clinical Oncology. 2021-01-29 - 9 citationsPhase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine P...Robert Wesolowski, Daniel G. Stover, Maryam B. Lustberg, Abigail B. Shoben, Meng Zhao
The Oncologist. 2020-08-01 - 12 citationsProspective Decision Analysis Study of Clinical Genomic Testing in Metastatic Breast Cancer: Impact on Outcomes and Patient Perceptions.Daniel G. Stover, Raquel E. Reinbolt, Elizabeth J. Adams, Sarah Asad, Katlyn Tolliver
JCO Precision Oncology. 2019-11-18
Journal Articles
- Modeling Combination Therapy for Breast Cancer with BET and Immune Checkpoint InhibitorsRobert Wesolowski, Andrew Stiff, Proceedings of the National Academy of Sciences
Press Mentions
- Bexion Pharmaceuticals, Inc. Announces Publication of Phase 1 Data for BXQ-350 in Advanced Solid TumorsOctober 31st, 2024
- Ohio State's Novel DHODH Inhibitor Enters First Human TrialsSeptember 16th, 2024
- Sanofi’s, AstraZeneca’s and Radius’ Oral SERDs Could Establish Clinical Worth in ER+ Breast Cancer by Showing Similar Efficacy to Faslodex, Experts SayApril 6th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: